EUVIMEDEUVIMED entdecken
Crossref

Biocatalytic cascades enable manufacture of the macrocyclic peptide enlicitide

Artis Klapars iD, Anna Fryszkowska iD, Stephanie Galanie iD, Omer Ad iD, Ellen Y Aguilera iD, Nnamdi Akporji iD, Chihui An iD, Stephanus Axnanda iD, Tewoderos M Ayele iD, Richard S Ayikpoe iD, Rodell C Barrientos iD, Matthew R Bauerle iD und 48 weitere

Science · 07.05.2026 · 392 (6798) · 643-647

DOI: 10.1126/science.aed8713 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science, erschienen am 07.05.2026. Verfasst von Artis Klapars und 59 weiteren Autor:innen. Beteiligte Einrichtung: Process Research and Development, Merck & Co., Inc., Rahway, NJ, USA. Hauptthemen laut MEDLINE: PCSK9 Inhibitors, Peptides, Cyclic, Oligopeptides, Macrocyclic Compounds. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Historically, many compelling therapeutic targets have been accessible only by injectable biologic drugs. Macrocyclic peptides, such as the proprotein convertase subtilisin/kexin type 9 inhibitor enlicitide for the treatment of atherosclerotic cardiovascular disease, are beginning to unlock these targets to orally administered therapies to enable broader patient access. We report the convergent biocatalytic assembly of enlicitide from simple building blocks enabled by a suite of engineered enzymes to catalyze selective peptide fragment formation, coupling, and macrocyclization in a protecting group–free manner. Together with efficient crystallizations that obviate the need for chromatography, this approach reduces the number of steps by greater than half compared with prior state-of-the-art methods, addressing long-standing synthetic challenges and offering a sustainable blueprint for the scalable development of complex peptide therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PCSK9 InhibitorsPeptides, CyclicOligopeptidesMacrocyclic CompoundsHumansBiocatalysisCyclizationProtein Engineering

Substanzen

PCSK9 InhibitorsPeptides, CyclicOligopeptidesMacrocyclic Compounds

Autor:innen und Institutionen

  • Process Research and Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Analytical Research and Development, Merck & Co., Inc., Rahway, NJ, USA.
  • Global Science, Engineering, and Commercialization, Merck & Co., Inc., Rahway, NJ, USA.
  • Discovery, Preclinical, and Translational Medicine, Merck & Co., Inc., Rahway, NJ, USA.

ORCID-Profile: Artis Klapars, Anna Fryszkowska, Stephanie Galanie, Omer Ad, Ellen Y Aguilera, Nnamdi Akporji, Chihui An, Stephanus Axnanda, Tewoderos M Ayele, Richard S Ayikpoe, Rodell C Barrientos, Matthew R Bauerle, Marc R Becker, Kevin M Belyk, Lisa Bereznitski, Jackson K B Cahn, Karla Camacho Soto, Louis-Charles Campeau, Kevin R Campos, Anagha Chandra, Hsieh Yao Darryl Chang, Mengbin Chen, Zhiwei Chen, Wai Ling Cheung-Lee, Cheol K Chung, Stephanie W Chun, Sarah S Co, Ryan D Cohen, Stephen M Dalby, Guilherme Dal Poggetto, Truc Do, Spencer D Dreher, Riki J Drout, Noah P Dunham, Yi Fan, Ryan M Flessner, Jacob H Forstater, Scott P France, Janaka C Gamekkanda, Donald R Gauthier, Agnieszka A Gil, Jacob W Greenwood, Noel Ha, Holst M Halsey, Clara Hartmanshenn, Yu He, Kaori Hiraga, Hsing-I Ho, Cynthia M Hong, Alan Hruza, Hang Hu, Alan M Hyde, Tetsuji Itoh, Chey M Jones, Woo-Ok Jung, Kanan Kanuga

Förderung

  • Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

Zitieren

APA

Klapars, A., Fryszkowska, A., Galanie, S., Ad, O., Aguilera, E. Y., Akporji, N., An, C., Axnanda, S., Ayele, T. M., Ayikpoe, R. S., Barrientos, R. C., Bauerle, M. R., Becker, M. R., Belyk, K. M., Bereznitski, L., Cahn, J. K. B., Soto, K. C., Campeau, L. C., Campos, K. R., …, & Kanuga, K. (2026). Biocatalytic cascades enable manufacture of the macrocyclic peptide enlicitide. Science, 392(6798), 643-647. https://doi.org/10.1126/science.aed8713

Vancouver

Klapars A, Fryszkowska A, Galanie S, Ad O, Aguilera EY, Akporji N, et al. Biocatalytic cascades enable manufacture of the macrocyclic peptide enlicitide. Science. 2026;392(6798):643-647. doi:10.1126/science.aed8713

BibTeX
@article{Klapars2026,
  author = {Klapars, Artis and Fryszkowska, Anna and Galanie, Stephanie and Ad, Omer and Aguilera, Ellen Y and Akporji, Nnamdi and An, Chihui and Axnanda, Stephanus and Ayele, Tewoderos M and Ayikpoe, Richard S and Barrientos, Rodell C and Bauerle, Matthew R and Becker, Marc R and Belyk, Kevin M and Bereznitski, Lisa and Cahn, Jackson K B and Soto, Karla Camacho and Campeau, Louis-Charles and Campos, Kevin R and Chandra, Anagha and Chang, Hsieh Yao Darryl and Chen, Mengbin and Chen, Zhiwei and Cheung-Lee, Wai Ling and Chung, Cheol K and Chun, Stephanie W and Co, Sarah S and Cohen, Ryan D and Dalby, Stephen M and Dal Poggetto, Guilherme and Do, Truc and Dreher, Spencer D and Drout, Riki J and Dunham, Noah P and Fan, Yi and Flessner, Ryan M and Forstater, Jacob H and France, Scott P and Gamekkanda, Janaka C and Gauthier, Donald R and Gil, Agnieszka A and Greenwood, Jacob W and Ha, Noel and Halsey, Holst M and Han, Xinxin and Hartmann, Michael and Hartmanshenn, Clara and He, Yu and Hernandez, Edgar and Hiraga, Kaori and Ho, Hsing-I and Hong, Cynthia M and Hruza, Alan and Hu, Hang and Hullen, Kari and Hyde, Alan M and Itoh, Tetsuji and Jones, Chey M and Jung, Woo-Ok and Kanuga, Kanan},
  title = {Biocatalytic cascades enable manufacture of the macrocyclic peptide enlicitide},
  journal = {Science},
  year = {2026},
  volume = {392},
  number = {6798},
  pages = {643--647},
  doi = {10.1126/science.aed8713}
}
Kostenlos starten →